<div class="entities" style="line-height: 2.5; direction: ltr">A 69-year-old woman with a history of 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypertension
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 presented with a generalized 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    petechial rash
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 and 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    shortness of breath
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 of 3 days duration.<br>The rash was nonpruritic, painless, and started at the thighs, but rapidly disseminated to the rest of the body.<br>She had progressive 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dyspnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 on exertion, with a significant 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    decrease in exercise tolerance
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
.<br>She denied 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    fever
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
, 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    headache
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
, 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dizziness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
, 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hemoptysis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
, or bleeding from anywhere.<br>There was no history of new drug use, unusual food intake, contact with any sick persons, or recent travel.<br>Her only medication was 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    enalapril
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
, which she had been taking for several years.<br>The patient denied any use of recreational drugs, tobacco, or alcohol.<br>On admission, she was 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    afebrile
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
, normotensive with mild 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tachypnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 (
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    respiratory rate of 22 breaths per minute
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
).<br>Physical examination revealed scattered 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    petechial rash
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
, more prominent in lower extremities, nonpalpable and nonblanching.<br>
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Chest auscultation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 revealed coarse 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    crackles
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 bilaterally.<br>Cardiovascular, abdominal, and neurological examinations were normal.<br>There was no palpable 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    lymphadenopathy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    visceromegaly
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.<br>Laboratory examination revealed 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    thrombocytopenia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (platelets 7000/mL), 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    anemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (hemoglobin 10.8 mg/dL and hematocrit 34%), and 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    leukocytosis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (white blood cells [WBCs] 11,600/mL).<br>The coagulation profile was normal, which excluded disseminated intravascular coagulation.<br>Arterial blood gas on ambient air revealed a partial pressure of oxygen (PaO2) of 64 Torr, a partial pressure of carbon dioxide (PaCO2) of 37 Torr (pH 7.45), and an increased alveolar-arterial gradient (44 Torr).<br>Diffuse airspace consolidation was found on chest roentgenogram (Fig.1A).<br>Computed tomography (CT) of the chest showed diffuse ground glass alveolar opacities and patchy infiltrates (Fig.1B, C).<br>She was started on 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    broad-spectrum antibiotics
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 and received intravenous 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    steroids
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
.<br>Peripheral smear showed giant platelets and occasional small platelet clumps, with no schistocytes.<br>A flexible fiber-optic bronchoscopy (FFB) showed normal mucosa with no endobronchial lesions (Fig.2A).<br>Serial aliquots of BAL fluid (BALF) turned more hemorrhagic, confirming the bronchoscopic diagnosis of 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DAH
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (Fig.2B).<br>Cytology of BALF showed a substantial amount of hemosiderin-laden macrophages, further supporting the diagnosis.<br>All BALF cultures and gram stains were negative.<br>The patient remained with severe 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    thrombocytopenia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 despite 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    steroids
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 and platelets transfusion.<br>High doses of pulse steroids and intravenous 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    immunoglobulins (
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>

<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    IVIGs
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
) were added with clinico-radiological improvement.<br>A bone marrow aspirate was morphologically normal.<br>Additional laboratory studies failed to reveal an etiology for secondary 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    thrombocytopenia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (Table  1), supporting the diagnosis of ITP.<br>Steroids were gradually tapered.<br>Repeat chest radiograph showed almost complete resolution of bilateral infiltrates (Fig.3).<br>Platelet count returned to normal by week 10 after admission without any additional therapies (Fig.4).<br>A 47-year-old woman presented to the hospital with a 1-month history of 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    abdominal distention
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
.<br>Physical examination revealed a huge mass in the lower abdomen.<br>The peripheral blood test showed elevated levels of carcinoembryonic antigen (CEA, 335.2 ng/mL [normal, &lt;5 ng/mL]) and carbohydrate antigen (CA) 125 (219 U/mL [normal, &lt;45 U/mL]) but a normal level of CA19-9 (9 U/mL [normal, &lt;37 U/mL]).<br>Computed tomography (CT) demonstrated a large, round mass with a maximum diameter of 15 cm in the pelvic cavity without the presence of ascites or pleural effusion (Fig.1a,  b).<br>Colonoscopy identified an elevated lesion with severe 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    stenosis in the sigmoid colon
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
, and histopathological examination of biopsy specimens from the tumor showed moderately differentiated 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    adenocarcinoma
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.<br>Although we scheduled an early operation, the patient developed acute 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dyspnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 and 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    general edema
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 2 weeks after the first CT scan.<br>The second CT scan examination demonstrated massive 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bilateral pleural effusion
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 with atelectasis and ascites (Fig.2a, b).<br>
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Thoracic drainage
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 and laparotomy were emergently performed.<br>Macroscopically, the tumor in the sigmoid colon had invaded the serosa, and the huge pelvic mass was found to contain a 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    right ovarian tumor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.        <br>Several small nodules of peritoneal dissemination were distributed over the greater omentum.<br>Perioperatively, 3800 mL of serous ascitic fluid was drained.<br>Cytodiagnosis of the fluid drained from the ascites and pleural effusion revealed no tumor cells.<br>Bilateral oophorectomy, total hysterectomy, omentectomy, and sigmoidectomy with regional node dissection were performed (Fig.3a).<br>Histopathological examination of the resected specimens showed moderately differentiated 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    adenocarcinoma
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in the tumors of both the ovaries and the sigmoid colon (Fig.3b).<br>The dissected paracolic nodes showed malignant cells.<br>Immunohistochemically, tumor cells from the ovaries and the colon both showed positive expression of 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cytokeratin 20
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 (CK20) but no expression of 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cytokeratin 7
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 (CK7), confirming that the 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ovarian tumors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 were metastases from primary 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    colon cancer
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (Fig.4a,  b).<br>The postoperative course was uneventful, and both 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pleural effusion
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 and ascites rapidly resolved.<br>Postoperatively, a regimen of 5-
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    fluorouracil
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 (5-FU), 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    leucovorin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
, and 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oxaliplatin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 (
<mark class="entity" style="background: #EC8FD0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    FOLFOX
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">VACCINE-RELATED</span>
</mark>
) was administered every 2 weeks for 5 months.<br>At 29 months after the first operation, the patient required curative hepatic resection for liver metastases.<br>At 78 months after the first operation, the patient remains alive with no evidence of a disease.<br>A 42-year-old woman presented with a 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    right breast lump
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
, lower 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    back pain
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
, 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    loss of height
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
, marked 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    kyphosis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hepatomegaly
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.<br>Core biopsies from the breast lump showed 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ductal carcinoma
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in situ (sample labelled P1.1; Supplementary Fig.1 and Supplementary Table 1).<br>An additional biopsy from an ipsilateral axillary lymph node (P1.2) revealed 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    metastatic ductal adenocarcinoma
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (ER+ (8/8) and HER2+ (3+)).<br>Computed tomography scan revealed widespread metastatic disease in bones, pleura and liver (Supplementary Fig.2 and Supplementary Table 2).<br>The patient was started on treatment with 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    trastuzumab
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 and 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    taxane-based chemotherapy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
, with a significant partial response (Supplementary Fig.3).     <br>After induction chemotherapy, she was maintained on 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tamoxifen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 and trastuzumab.<br>After 19 months on treatment, she presented with 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    seizures
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 and head computed tomography revealed a large 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    metastasis in the left frontal lobe
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 (Supplementary Fig.4), which was resected (M2.1).<br>Therapy with tamoxifen and trastuzumab was continued and collection of plasma samples was initiated (samples T1-T9).<br>Four months after surgery, she had 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    enlarging liver lesions
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 and a new 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    metastatic deposit in the left ovary
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 (Supplementary Fig.5).<br>Treatment was switched to a combination of 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    lapatinib
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 and 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    capecitabine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
, resulting in stable disease for 12 months (Supplementary Fig.6).<br>General deterioration then occurred, with disease progression in the chest (new pulmonary nodules, 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bilateral pleural effusions
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 and 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    posterior chest wall mass
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
, Supplementary Fig.7; 
<mark class="entity" style="background: #43B0F1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Eastern Cooperative Oncology Group
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">ORGANIZATION</span>
</mark>
 performance status 2-3).<br>Treatment was stopped and the patient died ~4 months later.<br>Tumour samples were obtained at diagnosis from the primary breast site (P1.1) and an axillary lymph node (P1.2); after 19 months from the brain metastasis area (M2.1); and at autopsy after 3 years on treatment (from the primary breast site, and from metastatic deposits in the chest, liver, ovary and vertebrae, labelled P3.1 and M3.1-M3.4, respectively).<br>Serial plasma samples were obtained over the last 500 days of clinical follow-up (T1-T9).<br>Tumour and plasma samples collected and the clinical course are summarized in Fig.1a,b.<br>An 8-year-old boy with S549R/1717-1G &gt; A genotype was started on 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ivacaftor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 (150 mg b.i.d.) on compassionate use.<br>At the age of 9 months he was diagnosed with 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CF
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 due to failure to thrive.<br>His previous history was remarkable for recurring 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nasal polyposis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 requiring endoscopic surgery and 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    exocrine pancreatic insufficiency
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 necessitating enzyme replacement therapy.<br>He grew with body weight and height along the 10th percentile.<br>He suffered from rather mild 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    respiratory symptoms
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
, primarily intermittent productive 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cough
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
, and had close to normal lung function parameters in previous years as measured by body plethysmography and spirometry (minimal z-score of FEV1: -1.2).<br>Sputum cultures grew 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Haemophilus influenzae
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Staphylococcus aureus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 on several occasions.<br>After 6 weeks of 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ivacaftor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 treatment, the patient reported clinical improvements in cough frequency, sputum production, physical performance, and less salt cravings.<br>He gained 1.4 kg in body weight without changing the dose of his 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pancreatic enzyme replacement
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 therapy.<br>His sweat chloride level (Macroduct(r)) decreased from 115 mmol/l before ivacaftor to 40 mmol/l after 6 weeks and 52 mmol/l after 41 weeks (normal &lt; 30 mmol/l [11]) of treatment.<br>His FEV1 increased from 1.25 L (-1.2 z-score) to 1.65 L (+0.5 z-score) after 41 weeks of ivacaftor therapy.<br>The LCI (normal &lt; 8) measured by N2-MBW decreased from 14.5 to 8.3 after 6 weeks and 7.8 after 41 weeks of ivacaftor treatment (Table 1 and Fig.1). <br>Here, we describe another case in a 60-year-old man from 
<mark class="entity" style="background: #B1D8B7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    San Francisco
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">LOCATION</span>
</mark>
 who had consumed raw pork while traveling in 
<mark class="entity" style="background: #B1D8B7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    the Philippines
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">LOCATION</span>
</mark>
.<br>In June 2003, this man became ill with 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    fever
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
, 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    diaphoresis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
, 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    headache
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
, 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nausea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
, and 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    anorexia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.<br>He had just returned from a 7-month vacation in 
<mark class="entity" style="background: #B1D8B7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    the Philippines
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">LOCATION</span>
</mark>
.<br>Three days after symptoms onset, his physician prescribed 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    doxycycline
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
.<br>Symptoms continued and he was admitted to a local hospital 5 days later with a 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    fever of 38.9degC,
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nuchal rigidity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
, 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    headache
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
, and general 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    malaise
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
.   <br>The patient described no recent contact with sick persons; past medical history was unremarkable.<br>On physical examination, he was somnolent but fully oriented, with no focal findings on neurologic examination and only slight nuchal rigidity.     <br>He had a leukocyte count of 21,000/mm3, including 16,400/mm3 neutrophils.<br>Cerebrospinal fluid (CSF) showed leukocyte count of 487/mL with 80% polymorphonuclear cells and 18% lymphocytes, and glucose and protein levels &lt;20 mg/dL and &lt;167 mg/dL, respectively.<br>Gram stain of CSF showed gram-positive cocci in pairs (Figure).<br>Empiric therapy (
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ceftriaxone
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
, 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    vancomycin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
, and 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ampicillin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
) for 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bacterial meningitis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 was begun.<br>Computed tomographic scan of the head showed only 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sinusitis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
; findings of chest radiograph and transesophageal echocardiogram were negative.<br>On hospital day 2, blood cultures grew gram-positive cocci in pairs and chains.<br>The organism was catalase-negative, 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bile esculin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
-negative, and 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pyrrolidonyl
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 aminopeptidase-negative, consistent with 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Streptococcus spp
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.<br>A latex agglutination test did not detect 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Streptococcus pneumoniae
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 antigen.<br>Antimicrobial susceptibility testing showed that the isolate was sensitive to 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    penicillin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 (MIC = 0.03), 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ceftriaxone
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
, and 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    vancomycin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 but resistant to 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tetracycline
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 and 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    clindamycin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
.<br>Antimicrobial therapy was changed to 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    penicillin G
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
, 24 million units intravenously per day.<br>On hospital day 5, the patient complained of 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hearing loss in his left ear
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
.<br>Results of nasopharyngeal endoscopy were negative.<br>By hospital day 7, the organism was identified by the API 20 Strep System (bioMerieux, 
<mark class="entity" style="background: #B1D8B7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Marcy l'Etoile, France
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">LOCATION</span>
</mark>
), as S. suis serotype 2.<br>The patient subsequently stated that he was a butcher with a culinary preference for partially cooked pork, which he had eaten in 
<mark class="entity" style="background: #B1D8B7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    the Philippines
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">LOCATION</span>
</mark>
 until the week prior to onset of symptoms.<br>On hospital day 9, a formal audiology evaluation showed severe bilateral 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sensorineural high-frequency hearing loss
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 (-70 dB).<br>The patient completed a 10-day course of 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    parenteral antimicrobial drugs
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 and was discharged on continued oral therapy with close followup.<br>Two months after discharge, the patient reported much improved hearing without other sequelae.<br>A 71-year-old African-American woman presented to the hospital with worsening 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    exertional dyspnoea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 associated with 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    orthopnoea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    lower extremity oedema
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 for 3 weeks.<br>She had a long-standing history of 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypertension
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and documented G6PD deficiency with prior episodes of 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    haemolysis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.<br>She was a former cigarette smoker and had family members with G6PD deficiency, hypertension and 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    diabetes mellitus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.<br>Vital signs measurement revealed a 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    blood pressure of 150/73 mm Hg
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
, pulse rate of 70 bpm, respiratory rate of 24 breaths/min, 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    temperature of 36.6degC and
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 97% saturation on room air.<br>She was comfortable at rest.<br>Her physical examination showed 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    distended jugular veins
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
, 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    inspiratory crackles in bilateral lung bases
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
, a 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    laterally displaced apical impulse
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 and 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bipedal oedema
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.<br>The ECG showed 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    left ventricular hypertrophy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 and 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    inferolateral T-wave inversions
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
.<br>Chest radiography revealed 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cardiomegaly
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 and mild 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pulmonary oedema
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.<br>The metabolic panel and troponin levels were normal but the B-type natriuretic peptide was increased at 826.5 pg/mL.<br>Echocardiography showed a dilated left ventricle with an ejection fraction (EF) of 30% and mild 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    right ventricular systolic dysfunction
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
.<br>Coronary artery catheterisation revealed normal coronary circulation.<br>
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Ethacrynic acid
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 at 50 mg daily was chosen for 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    diuresis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.<br>She improved after a day but still had 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dyspnoea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, so we added 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    spironolactone
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
.<br>Subsequently, 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    metoprolol
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 succinate and 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    losartan
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 were included in the regimen.<br>Repeat chest radiography showed resolution of 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pulmonary oedema
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.<br>The patient's laboratory results during her hospital stay did not show signs of haemolysis 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 worsening 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    kidney function
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
.<br>She did not develop ototoxicity and was discharged home asymptomatic.<br>A 61-year-old male was referred to the emergency department by his general practitioner in April 2010 for investigation of 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    loose bowel motions
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 and an episode of 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    black stool
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
.<br>The patient had a history of 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    insulin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>

<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    -dependent type II
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    diabetes mellitus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypertension
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ischaemic heart disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with two previous ischaemic events, 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obstructive sleep apnoea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    depression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    schizophrenia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and a previous 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    incisional hernia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 repair.<br>On examination, he was morbidly obese (BMI 45) and was noted to have marked 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hepatomegaly
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.<br>This was not associated with any recent 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    weight loss
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
, 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    haematemesis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
, 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    jaundice
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 or 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    abdominal pain
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
.<br>The patient denied previous blood transfusions, usage of intravenous drugs and did not drink alcohol.<br>A faecal occult blood test was negative, and the patient's last colonoscopy 2 years prior was unremarkable.<br>He was referred to our tertiary centre for further management after an ultrasound scan (USS) displayed an ovoid mass of mixed echogenicity arising from the liver, measuring 12 x 9 cm.<br>A computed tomography (CT) scan confirmed a malignant appearing, pedunculated lesion attached to segment IV (Fig.1).<br>A subsequent magnetic resonance imaging (MRI) confirmed that on T2 weighted imaging (WI), the lesion was isointense to the liver peripherally with central branching hyperintensities (Fig.2a) which corresponded to the hypointensities seen on T1WI (Fig.2b).<br>Enhancement of the lesion was noted in arterial phase (Fig.3a), during portal venous phase (Fig.3b) and at 2 min (Fig.3c), with some central areas of non-enhancement.<br>The lesion becomes slightly hypointense on delayed images at 10 (Fig.3d) and 20 min compared to the surrounding liver.<br>Laboratory investigations revealed a mildly elevated gamma-glutamyl transpeptidase of 137 IU/L (normal 5-50 IU/L).<br>
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Hepatitis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 screen, alpha-fetoprotein, carcinoembryonic antigen and 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cancer
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 antigen 19-9 were all unremarkable.<br>The patient underwent a subsegmental resection of the 15 cm segment IVb mass in June 2010.<br>There was severe 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hepatic steatosis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, but no 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cirrhosis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.<br>The patient was discharged postoperative day seven without complications.<br>Pathology of the resection specimen confirmed SFTL.<br>The specimen displayed a pale tan nodular appearance with a firm and rubbery cut surface.<br>Histological examination revealed fascicles of spindle cells in storiform arrangement with a pushing margin.<br>There was evidence of extracellular collagen deposition, areas of myxoid stroma and branching vessels with hyalinisation.<br>The specimen displayed a high mitotic rate of up to 9 per 10 high-power fields (HPF) with no necrotic or haemorrhagic features.<br>Immunohistochemistry showed positive staining for CD34, CD99 and BCL-2.<br>The tumour was negative for c-Kit, CD31, SMA, 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    desmin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
, 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cytokeratins
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 (AE1/AE3, MNF116 and Cam 5.2), EMA and S100.<br>The margins were clear.<br>The non-neoplastic remainder of the liver displayed 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pericellular fibrosis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 indicative of 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    steatohepatitis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.<br>The patient was followed-up regularly every 4 to 6 months with CT scans by the local general practitioner who liaised with the consultant surgeon.  <br>There were two episodes of re-admissions for further investigation of recurrent 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    right upper quadrant pain
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 between 2011 and 2013.<br>Multiple MRI scans performed during this period revealed expected postsurgical changes with no tumour recurrence.<br>However, in May 2016, the patient presented to his local emergency department with progressively worsening right upper quadrant pain and increasing 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dyspnoea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with an oxygen demand.<br>CT of his chest, abdomen and pelvis revealed extensive tumour recurrence adjacent to the previous resection site (Fig.4).<br>In addition, there was a clinically significant 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    right-sided pleural effusion
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 and a 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pleural mass at the right lung base measuring 3.8 cm
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 (Fig.5).    <br>Pleurocentesis was performed, draining 1400 ml of serosanguineous fluid.<br>Cytology was negative for malignant cells.<br>The case was discussed extensively in a multi-disciplinary setting, and it was decided given the patient's two sites of disease and significant perioperative risk that he was not a candidate for radical reoperation.<br>There were also no suitable chemo- or radiotherapeutic therapies available.<br>The patient was subsequently referred to the palliative team for management of his symptoms and discharged back to the community.<br>He was still alive 1 month after discharge.<br>This young boy is the first child of healthy non-consanguineous, white 
<mark class="entity" style="background: #B1D8B7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    British
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">LOCATION</span>
</mark>
 parents.<br>He was born at term following an uneventful pregnancy weighing 3132 g (9th-25th centile).<br>Early development was thought to be normal.<br>At approximately 6 months of age he developed 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tonic upward eye deviation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 associated with 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    flexion of his arms and neck
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 consistent with 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    infantile spasms
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.<br>An electroencephalograph (EEG) at this time was grossly abnormal (
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypsarrhythmia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
) and strongly supported a diagnosis of 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    West Syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.<br>Cranial MRI was reported as normal.<br>
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Prednisolone
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 was prescribed and treated the 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    seizures
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 effectively.<br>
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Steroids
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 were weaned over 6 weeks and he remained seizure free for a further 6 months.<br>By the age of 1 year, it was apparent that his early developmental progress was not being maintained and that he was functioning at the 6-8 month developmental stage.<br>
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Seizures
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 returned shortly after his first birthday and were prolonged, frequent and on occasion focal, involving his right arm, leg and right side of face.<br>
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Clonazepam
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 briefly improved seizure frequency, but subsequently his 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    epilepsy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 has proved refractory to various combinations of anticonvulsant therapy.<br>Prolonged 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    seizures of more than 60 min
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 have been associated with a stepwise regression in his neurodevelopment.<br>Seizure semiology is now predominantly one of 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    epilepsia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 partialis continua involving the right side of his face, right arm and right leg.<br>The development of 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    focal seizures
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 and the progressive nature of the condition prompted a second cranial MRI at the age of 2 years 6 months.<br>By contrast with the previous scan, this MRI revealed symmetrical 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    subcortical white matter lesions
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 (Fig.1A) with 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    thinning of the anterior and genu of the corpus callosum
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 (Fig.1B).<br>On examination, the patient had small, round, anteriorly rotated ears and a broad nasal root.<br>He demonstrated no visual awareness but startled to loud noise.<br>
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Tone was increased in all 4 limbs
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 with internal rotation of both legs at the hips.<br>Reflexes were pathologically brisk.<br>Brief 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myoclonic jerks
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 were evident throughout the examination.<br>A 33-year-old 
<mark class="entity" style="background: #B1D8B7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Moroccan
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">LOCATION</span>
</mark>
 man with a 5-month history of recurring 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sinusitis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 presented with 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    temperature
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
, 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myalgia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cough
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
, and 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hemoptysis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.<br>Thoracic physical examination revealed reduced vesicular murmur, and chest X-ray showed bilateral diffuse alveolar infiltrates.<br>Laboratory analyses showed elevation of acute-phase proteins (CRP 26 mg/dL) and 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    creatinine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 (1.2 mg/dL) with 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nonnephrotic proteinuria
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    microscopic glomerular hematuria
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.<br>An antibiotic therapy for community acquired and atypical 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pneumoniae
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    levofloxacin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 500 mg daily iv was established, but on the 3rd day from admission the patient developed 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    respiratory failure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 unresponsive to noninvasive ventilation and had to be intubated.<br>
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    White lung
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with consolidations and ground glass areas at computed tomography scan (Fig.1), 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    diffuse airways bleeding
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 at fiberoptic bronchoscopy, mild 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    normocytic anemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (9 g/dL), and ANCA-PR3 positivity (18.9 U/mL) were consistent with the diagnosis of 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    GPA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.<br>Despite maximal ventilatory support, gas exchange did not improve (pH 7.33, PaO2 71 mm Hg, PaCO2 51 mm Hg, HCO3- 25 mmol/L, SaO2 94%) requiring extracorporeal membrane oxygenation (ECMO).<br>Treatment with high-dose 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    methylprednisolone
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 (1 g daily for 3 days and 1 mg/kg daily thereafter), 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cyclophosphamide
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 (1.2 g/pulse every 2 weeks for the 1st 3 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pulses
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
, followed by infusions every 3 weeks for the next 2 pulses), and plasma exchange (PE), according to 
<mark class="entity" style="background: #43B0F1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    European vasculitis study group
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">ORGANIZATION</span>
</mark>
 recommendations,[4] was immediately started with 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    respiratory improvement
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 that allowed ECMO and 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    orotracheal tube withdrawal
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 and subsequent discharge from intensive care unit.<br>After 9 days from the beginning of treatment ANCA-PR3 levels normalized (3 U/mL).<br>Two months later, after the 5th bolus of 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cyclophosphamide
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 and with 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    prednisone
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 0.3 mg/kg/day, the patient complained 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arthromyalgia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    testicular pain
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 with 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    edema
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
, 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cough
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
, and 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    shortness of breath
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
: laboratory data showed 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    worsening of renal function
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
, mild 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    anemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoxemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (PaO2 61 mm Hg).       <br>Epididymitis was confirmed by ultrasound.<br>Because of rapidly progressive 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    renal failure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 (estimated glomerular filtration rate 35 mL/min) renal biopsy was performed and showed prominent intracapillary and extracapillary proliferation, with the formation of some 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    fibrocellular crescents
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 and 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    focal capillary necrosis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 (Fig.2).<br>Lung computed tomography-scan and fiberoptic bronchoscopy also confirmed 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    alveolar hemorrhage
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 relapse.<br>Treatment with high-dose 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    methylprednisolone
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 (1 g daily for 3 consecutive days) and 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    rituximab
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 (375 mg/m2 weekly for 4 weeks) was started with rapid resolution of urologic and pulmonary involvement but delayed and partial improvement of renal function.<br>At a 1-year follow-up, the patient is alive and under treatment with 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    azathioprine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 (150 mg daily) and 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    prednisone
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 (15 mg daily).<br>Renal function has markedly improved (estimated glomerular filtration rate 94 mL/min) same as gas-exchange (pH 7.42, PaO2 86 mm Hg, PaCO2 36 mm Hg, HCO3- 23 mmol/L, SaO2 95%).<br>The patient signed institutional informed consent form at the time of admission to hospitalization.<br>An approval by ethics committee was not necessary because of the routine health care.<br>A 49-year-old woman was admitted to 
<mark class="entity" style="background: #43B0F1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    the Department of Radiology of the Second Affiliated Hospital of Zhejiang University
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">ORGANIZATION</span>
</mark>
 in October 2004 with 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    right upper quadrant pain
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 and 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    weight loss
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
.<br>She was a 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hepatitis B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 virus carrier.<br>Her a-fetoprotein level was 1185.3 ng/mL.<br>Ultrasonography and computed tomography (CT) revealed a 10-cm mass in the posterior segments of the right liver lobe.<br>A 1.5-cm mass was also found in the left lateral segment.<br>These clinical signs indicated that the patient had inoperable 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    HCC
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Child-Pugh class A cirrhosis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.<br>TACE was offered to the patient.<br>Angiogram demonstrated no obvious 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hepatic arterio-
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
venous shunt, but multiple smaller masses in both lobes of the liver.<br>An emulsion of 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    oxaliplatin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
, 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pirarubicin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
, 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hydroxycamptothecin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 and 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    lipiodol
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 were prepared, 35 mL and 3 mL of the mixture were administered intra-arterially to the right and left hepatic artery, respectively.<br>The patient experienced 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    right upper quadrant pain
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 after TACE and had an uneventful recovery.<br>One month later, a second TACE procedure was performed via the right hepatic artery and 40 mL of the mixture was administered.<br>On the next day, she experienced sudden acute 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dyspnoea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and the peripheral oxygen saturation decreased to 90%.<br>The chest X-ray showed some increased reticular shadows in the left lung, especially in the lower zones, and a chest CT scan revealed multiple iodized oil-like high-density materials in parenchyma of the lung (Figure  1).<br>After 10 mg 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dexamethasone
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 i.v. and other supportive therapies were administered, the respiratory symptom was attenuated.<br>Two days later, the patient suffered from a serious 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    headache
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 and transient 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    consciousness loss
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
, accompanying 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nausea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 and 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    vomiting
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 followed by 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    confusion
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
, 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    lower extremity weakness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
.<br>Non-contrast enhanced CT scanning showed multiple disseminated hyper-
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    intense lesions in the brain
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
, consistent with deposition of iodized oil (Figure  2).<br>One week later, her 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    respiratory and neurologic symptoms disappeared
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 completely, and she was discharged.<br>The patient also consequently completed the other three TACE procedures, during which no similar symptoms occurred.<br>A 39-year-old Korean male come to our hospital complaining of 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cough
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
, 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myalgia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    fever
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 that had lasted for 5 days.<br>He was a company worker and denied any previous medical histories.<br>He was a current smoker and drank alcohol about once a month.<br>His vital signs were: 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    blood pressure, 100/60 mmHg
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
, heart rate, 100/min, respiratory rate, 25 breaths/min, and 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    body temperature, 39 degC.
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
<br>On the physical examination, 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    decreased breathing sound
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 was noted in the right lower lung.<br>Laboratory tests revealed a c-reactive protein (CRP) level of 119 mg/dL, a total bilirubin level of 1.8 mg/dL, and 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    alanine transaminase
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 and 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    aspartate transaminase
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 levels of 250 and 172 IU/L, respectively.<br>His platelet count was 98,000/mm3, while his white cell count was 8150/mm3 (neutrophil: 85%).<br>In the arterial blood gas analysis checked in room air, pH, PaCO2, PaO2, bicarbonate, and oxygen saturation levels were 7.50, 34 mmHg, 67 mmHg, 26.5 mmol/L, and 95%, respectively.<br>A test for the human immunodeficiency virus was negative.<br>
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Mycoplasma
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Chlamydia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 antibodies were negative.<br>
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Streptococcal
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Legionella
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 urinary antigens were negative.<br>Anti-nuclear and anti-neutrophilic cytoplasmic antibodies were also negative.<br>A chest X-ray showed consolidation in the right mid to lower lung fields.<br>Chest computed tomography showed consolidation with surrounding ground glass opacity in the right middle lobe with a small amount of pleural effusion in the right hemithorax (Fig.1).<br>Abdominal sonography revealed no abnormal finding in the hepatobiliary system.<br>We began to administer 4 L/min of oxygen nasally and empirical antibiotics with third generation 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cephalosporin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 and 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    macrolide
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 following a diagnosis of community
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    -acquired pneumonia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.<br>On the second day in the hospital, the patient's fever was sustained and he complained of dyspnea.<br>His hypoxemia was aggravated such that he required 7 L/min of oxygen via a simple mask and the consolidation and pleural effusion had markedly progressed (Fig.2a).<br>We performed bronchoscopy and thoracentesis.<br>Multiplex real-time reverse transcriptase polymerase chain reaction (RT-PCR) for respiratory viruses using bronchoalveolar lavage fluid was positive for human adenovirus while other microbiological studies were negative.<br>Pleural fluid was lymphocyte-dominant exudate and was also positive for human adenovirus.<br>Under the diagnosis of adenovirus 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pneumonia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, we started antiviral therapy with oral 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ribavirin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 400 mg q 12 h while maintaining 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    antibiotics
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
.<br>On hospital day 4, his 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    fever
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 had subsided and symptoms were much improved.<br>The transaminase levels, CRP and platelet counts gradually normalized (Fig.3).<br>A follow-up chest X-ray was clear (Fig.2b) and he was discharged in hospital day 13 without any complications.<br>A 60-year-old white Brazilian man, with controlled 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypertension
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    stage 2
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obesity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 presented to our institution with a complaint of progressive fatigue with moderate to light exertion of approximately 1 year's duration.<br>During that period, he had undergone 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myocardial perfusion scintigraphy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 without evidence of 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obstructive ischemic disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.<br>He had no clinical evidence of 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    systolic heart failure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.<br>He had undergone biological mitral valve replacement 3 years previously for 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    mitral valve stenosis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and had undergone ablation of 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    atrioventricular nodal reentry tachycardia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 18 months previously.<br>At the time of valve replacement, there was no reported evidence of pulmonary 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arterial hypertension
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.<br>The patient's medication list included aspirin 100 mg/day, carvedilol 50 mg/day, atorvastatin 10 mg/day, and losartan 25 mg/day.<br>His echocardiogram showed normal function of a mitral prosthesis, global left ventricular systolic function within normal limits (left ventricular ejection fraction 62 % measured using the 
<mark class="entity" style="background: #870A30; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Teichholz
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
 method), 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    stage I diastolic dysfunction
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and mean 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pulmonary arterial systolic blood pressure of 50 mmHg
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
.<br>In the 6-minute walk test, the patient walked 104 meters (Table 1).<br>Catheterization of his right heart chambers and pulmonary arteries confirmed the diagnosis of 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pulmonary hypertension
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (Table 2).<br>During the follow-up period, therapy with 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nifedipine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 and 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sildenafil
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 was not tolerated secondary to 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    orthostatic hypotension
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.<br>The patient was referred for radiofrequency ablation of the pulmonary artery trunk for the treatment of 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    refractory pulmonary hypertension
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.<br>The procedure was performed in the catheterization laboratory with direct visualization using fluoroscopy and radiopaque contrast dye.<br>The patient remained under unconscious sedation.<br>Catheterization of the right femoral artery via the standard Seldinger technique was performed using an 8-French valved short sheath after subcutaneous injection of a local anesthetic.<br>Subsequently, this sheath was replaced with a steerable long sheath (
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Agilis(r
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
); 
<mark class="entity" style="background: #43B0F1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    St. Jude Medical
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">ORGANIZATION</span>
</mark>
, 
<mark class="entity" style="background: #B1D8B7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    St. Paul
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">LOCATION</span>
</mark>
, 
<mark class="entity" style="background: #B1D8B7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    MN
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">LOCATION</span>
</mark>
, 
<mark class="entity" style="background: #B1D8B7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    USA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">LOCATION</span>
</mark>
) using the standard over-the-wire technique.<br>Unfractionated 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    heparin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 was administered intravenously, targeting an activated coagulation time between 250 and 350 seconds.<br>Electroanatomic reconstruction of both the right ventricular outflow tract and pulmonary artery was performed using the 
<mark class="entity" style="background: #43B0F1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    EnSite Velocity Cardiac Mapping System
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">ORGANIZATION</span>
</mark>
 (
<mark class="entity" style="background: #43B0F1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    St.Jude Medical
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">ORGANIZATION</span>
</mark>
) under direct fluoroscopic visualization, and a merger was made with the formatted image obtained by performing cardiac computed tomography angiography (Fig.1).<br>The Agilis(r) sheath was advanced into the right ventricular outflow tract just before reaching the pulmonary valve.<br>Through this long sheath, we introduced an ablation catheter with an open irrigated tip (
<mark class="entity" style="background: #43B0F1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    St.Jude Medical
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">ORGANIZATION</span>
</mark>
).<br>The parameters used for each application according to our protocol were as follows: power of 5 W, maximum temperature of 48 degC, 60-second duration in each spot, maximum impedance variation of 10 % from baseline values, and an irrigation flow rate of 17 ml/minute, which created a circle in the pulmonary artery trunk.<br>The patient was discharged the next morning.<br>No noteworthy changes before or after the procedure or before discharge in the patient's radiographic or echocardiographic laboratory parameters were seen.<br>The patient's blood pressure in both the right heart chambers and the pulmonary artery were determined using catheterization before and at 3 and 6 months after the procedure.<br>The results are shown in Table 2.<br>At the patient's 3-month follow-up examination, he showed an improvement in functional class for fatigue with major exertion.<br>He also demonstrated an increased distance walked in the 6-minute walk test and reduction of the pressures in both the right cavities and the pulmonary artery.<br>Currently, with 6 months of clinical follow-up, he has maintained his improvement in functional classification and is pedaling his bicycle.<br>A 60-year-old male patient had previously undergone a radical resection of a T2bN0M0G3 Stage III 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    retroperitoneal sarcoma
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, including right nephrectomy and cholecystectomy, in 2002.<br>Pathologic evaluation demonstrated a 25 cm high-grade liposarcoma with different histologic components, including myxoid, round cell, well-differentiated, sclerosing and pleomorphic patterns.<br>Surgical margins were negative as the tumor did not invade the kidney, and since the renal vein and ureter were free of tumor as well.<br>The patient did not undergo any additional therapy.<br>Surveillance magnetic resonance imaging in 2007 revealed an isolated tumor recurrence in the retroperitoneum.<br>An exploratory celiotomy revealed tumor involvement of the duodenum, head of the pancreas, superior mesenteric vein, vena cava and left renal vein with severe 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    adhesive changes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
, leading to the intraoperative assessment of unresectable disease.<br>Subsequently, the patient underwent stereotactic body radiation to the retroperitoneal tumor in five fractions for a total dose of 30 Gy, without complication.<br>Postradiation imaging revealed near complete resolution of the retroperitoneal mass.<br>One year later, the patient presented with 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    weight loss
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
, 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    postprandial abdominal pain
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
, 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nausea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 and 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    vomiting
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
.<br>Cross-sectional imaging revealed a 7 cm mass with involvement of the third portion of the duodenum (Figure  1).<br>However, there was no obvious involvement of the pancreatic head or the other structures that were noted to be involved during the previous laparotomy.<br>We elected to perform another resection attempt, including a possible pancreatoduodenectomy or retroperitoneal vascular resection if necessary.     <br>At exploration, the residual tumor was an entirely intraduodenal, pedunculated mass at the posterior duodenal wall distal to the ampulla that filled the entire duodenal lumen.<br>The patient underwent a duodenotomy and stalk transection of the polypoid mass, followed by partial duodenal resection with hand-sewn 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    duodenojejunal anastomosis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (Figure 2).<br>Surgical pathology examination revealed a 9.5 cm recurrent 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    high-grade
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    liposarcoma
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with polypoid intraluminal growth containing myxoid, round cell, well-differentiated, sclerosing and focally pleomorphic areas.<br>Surgical margins were negative as the tumor came within 0.1 cm of the stalk margin and there was no evidence of additional neoplastic components within the remaining resected duodenum.<br>The postoperative course was uncomplicated, and the patient has demonstrated no recurrence up to 30 months from this resection.<br>A 52-year-old man with a 30-year history of smoking presented with an abnormal nodule measuring 0.8 x 1.5 cm in the left upper lung lobe imaged through chest computed tomography (CT) scanning in March 2012 in a community hospital.<br>He had previously been well without any additional relevant or abnormal symptoms.<br>Physical examination suggested no significant abnormalities.<br>Laboratory findings were within normal range, except for a carcinoembryonic antigen (CEA) level of 30.25 ng/mL (normal range, 0-5 ng/mL) found in the serum.<br>Subsequently, a positron emission tomography (PET)/CT scan showed a 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    lung lesion
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 with a standardized uptake value of 7.94, which was highly suspected to be a malignant tumor (Fig.1).<br>Subsequently, he underwent left upper lung lobectomy and lymph node dissection.<br>Postoperative pathological examination revealed an 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    adenocarcinoma
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ADC
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) (Fig.2A).<br>Immunohistochemistry (IHC) staining results were positive for CK7, TTF-1, p63, and NapsinA and negative for CK 5/6, Syn, cgA, and Ki-67 (20%-30%).  <br>The clinical stage was classified as IA2 (pT1bN0M0).<br>Because the tumor was still in an early stage, the patient did not receive adjuvant treatment but continued to be monitored through regular hospital visits every 3 months.<br>The patient's condition had been stable until the onset of left 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    chest pain
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 in April 2015.<br>The patient was transferred to our hospital (a tertiary care hospital) for further treatment.<br>Physical examination suggested a significant tender 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    point in the left chest wall.
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
<br>Laboratory findings showed only a single parameter outside the normal range: the cytokeratin19 fragment antigen 21-1 (CYFRA21-1) level was 17.45 ng/mL in the serum (normal range = 0-3.3 ng/mL).<br>CT and PET/CT scans highlighted the serious involvement of left pleura, showing bilateral lung lesions (Fig.3A and E).<br>At that point, the clinical stage was upgraded to IVB.<br>After the CT-guided left pleura puncture, pathological IHC analysis showed positive staining for p63, p40, CK 7, and CK 5/6, while TTF-1 and NapsinA staining were absent, supporting a diagnosis of 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    squamous cell carcinoma
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SCC
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) (Fig.2B).<br>Meanwhile, molecular evaluation confirmed an L858R mutation in exon 21 and a T790M mutation in exon 20 (Fig.4B and C).<br>Considering the pathology of the SCC was quite distinct compared with that of the originally resected NSCLC specimen, we retrospectively reassessed the surgery specimen to verify our primary diagnosis.<br>The morphologic and IHC results were in complete agreement with the initial diagnoses, but an L858R mutation was identified using the newly added molecular evaluation (Fig.4A).<br>To relieve the acute 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pain in the left pleura
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 as quickly as possible, palliative three-dimensional conformal radiotherapy (3D-CRT) for the 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    chest lesion
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 was delivered at a total dose of 42 Gy/14 fractions (f), once daily and 5f/week (Fig.5).<br>The volume over radiation dose 5 Gy (V5) values of the left, right, and total lungs were 20%, 0%, and 7.8%, respectively; the volume over radiation dose 20 Gy (V20) values were 10%, 0%, and 5%, respectively; the mean lung dose (MLD) was 5 Gy.<br>Meanwhile, considering the MST pathology was that of 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SCC
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, the patient received GP chemotherapy (
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cisplatin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 75 mg/m2 d1, 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    gemcitabine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 1250 mg/m2 d1, d8, for 21 days as a cycle) for 4 cycles, and the patient achieved partial remission (PR) after 2 cycles, followed by stable disease (SD) after 4 cycles (Fig.3[B3[B and F] and [C and G]) according to response evaluation criteria in 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    solid tumors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (RECIST) 1.1.<br>Then, 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    gefitinib
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 (150 mg qd) was used as maintenance treatment from November 2015 onward.<br>During the treatment, 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Ibandronate
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 sodium was given monthly for skeletal-related events.<br>The patient is currently under surveillance with SD (Fig.3D and H) and with PS scores of 0.<br>A 63-year-old male patient without smoking or drinking history was admitted on June 11, 2014.<br>His major complaints were gradually aggravated 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dysphagia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 and 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    fatigue
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
, on suspicion of 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    obstructive disease in upper digestive tract
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.<br>He had been an athlete before, and then retired in good physical status before admission.<br>His family and social history indicated nothing abnormal.<br>Thorough physical examination of his skin, oral mucosa, eyes, and genital areas failed to identify any superficial lesions.<br>Additionally, laboratory tests including hepatic function, renal function, and serum tumor markers such as carcinoembryonic antigen, cytokeratin 19 fragment, 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    squamous cell carcinoma
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neuron-specific enolase
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, and carbohydrate antigen 125 were all in normal range.<br>Therefore, further endoscopic and radiological examinations were carried out for accurate diagnosis.<br>Endoscopic examination revealed a slightly pigmented, irregular mass, which was located in lower esophagus, measuring 5.0 cm x 3.0 cm in size.      <br>Fine needle biopsy of the lesion revealed 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    esophageal melanoma
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, which was confirmed by histopathology.<br>Besides chest and abdomen computed tomography (CT), enhanced cranial magnetic resonance image (MRI) and bone emission computed tomography (ECT) showed enlarged mediastinal, nd also celiac lymph nodes (Fig.1A), without obvious involvement of supraclavicular lymph nodes.<br>Concurrently, the CT showed an isolated, irregular 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pulmonary tumor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (Fig.1B).<br>Positron emission tomography was not carried out, because it was not covered by health insurance of this patient.<br>Therefore, this patient was clinically staged as cT3NxM1 according to the 7th edition of 
<mark class="entity" style="background: #43B0F1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    American Joint Committee on Cancer
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">ORGANIZATION</span>
</mark>
 TNM staging system for 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    esophageal cancer
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.<br>CT-guided percutaneous pulmonary biopsy was avoided, with the aim to diminish the risk of tumor dissemination.<br>Single-stage resection of the esophageal and pulmonary lesions was assumed to be reasonable after multidisciplinary consultation, which was approved by 
<mark class="entity" style="background: #43B0F1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Ethical Committee
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">ORGANIZATION</span>
</mark>
 of 
<mark class="entity" style="background: #43B0F1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Xuzhou Central Hospital
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">ORGANIZATION</span>
</mark>
.<br>Because the prognosis of this patient probably was extremely poor without targeted antibodies, which he could not afford for financial reasons.     <br>After his informed consent, simultaneous 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Ivor-Lewis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 esophagectomy and 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    right upper lobectomy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 were performed successfully, under general anesthesia, after double-lumen endotracheal intubation, followed by systemic dissection of lymph nodes located in mediastinum and abdomen, in accordance with the principles of oncological surgery.<br>The operation time was 290 minutes, without obvious 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bleeding
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 during the surgery.<br>Postoperative pathological staining of the specimen revealed pleomorphic cells and abundant melanin granules (Fig.1C), whereas immunohistochemical tests demonstrated positive expression of human melanoma black 45 (HMB45), microtubule-associated protein tau 1 (MAPT1), 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    melan A
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 and S100, and negative expression of 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    desmin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
, 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    synaptophysin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
, and epithelial membrane antigen (EMA), which was consistent with melanoma.<br>The resection margin and dissected lymph nodes were pathologically tumor-negative.<br>In addition, molecular study of the patient indicated mutation of 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    V-raf murine sarcoma
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    viral oncogene homolog
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 B1 (BRAF) V600E.<br>Based on these findings, a diagnosis of advanced 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PMME
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 was tentatively established as stage IV (pT3N0M1), because there was insufficient evidence to distinguish synchronous primary 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pulmonary melanoma
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 from metastasis for this patient.<br>The postoperative recovery was mainly uneventful, and the patient was discharged 14 days after surgery.<br>Subsequently, 4 cycles of adjuvant conventional chemotherapy with an interval of 3 weeks were completed, with controlled moderate toxic effects including 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    thrombocytopenia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
, 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    leukopenia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
, 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nausea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
, 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    vomiting
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
, and 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    diarrhea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
.<br>The detailed chemotherapy regimen is as follows: 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    paclitaxel liposome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 for injection on day 1 and day 8 (135 mg per square meter of body surface area; 
<mark class="entity" style="background: #43B0F1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Nanjing Luye Sike Pharmaceutical Co.
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">ORGANIZATION</span>
</mark>
, Ltd., 
<mark class="entity" style="background: #B1D8B7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Jiangsu
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">LOCATION</span>
</mark>

<mark class="entity" style="background: #B1D8B7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    , China
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">LOCATION</span>
</mark>
.), 
<mark class="entity" style="background: #EC8FD0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tegafur injection
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">VACCINE-RELATED</span>
</mark>
 on day 2 to 4 (1000 mg per square meter of body-surface area; 
<mark class="entity" style="background: #43B0F1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Shandong Qilu Pharmaceutical Co., Ltd.
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">ORGANIZATION</span>
</mark>
, 
<mark class="entity" style="background: #B1D8B7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Jinan
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">LOCATION</span>
</mark>
, China.) plus cis-platinum on day 2 to 3 (75 mg per square meter of body-surface area; Shandong Qilu Pharmaceutical Co., Ltd., Jinan, China).<br>This patient suffered from moderate 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    leukopenia/
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myelosuppression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 after the second cycle of 
<mark class="entity" style="background: #EC8FD0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TPF chemotherapy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">VACCINE-RELATED</span>
</mark>
, and he recovered quickly after the administration of 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    granulocyte colony-stimulating factor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 (G-CSF).<br>Concurrently, recombinant human 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    interferon alpha-2b
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 (
<mark class="entity" style="background: #43B0F1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Harbin pharmaceutical group biological engineering Co., Ltd
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">ORGANIZATION</span>
</mark>
, Harbin, 
<mark class="entity" style="background: #B1D8B7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    China
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">LOCATION</span>
</mark>
) was administrated via 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypodermic injection
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 thereafter (6000 units every 3 days; Fig.2), lasting for 1 year.<br>The patient was followed up continuously after the surgery.<br>Chest and abdomen CT, cranial MRI, bone ECT, and thorough physical examination were carried out every 3 months.<br>Encouragingly, the patient survived without loco-regional recurrence or remote metastasis during the follow-up of two and a half years up to now (Fig.3).<br>A 51-year-old man was referred to our hospital due to severe 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    congestive heart failure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ventricular arrhythmias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 in March 2008.<br>He had been suffering from 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    heart failure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ventricular tachycardia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 for years despite receiving the conventional treatment (ie, 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    furosemide
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
, 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    lisinopril hydrate
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
, 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pimobendan
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
, 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    warfarin potassium
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
, 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    carvedilol
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
, 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    metildigoxin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 and 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    amiodarone hydrochloride
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
).<br>His height was 161 cm and body weight was 83 kg.<br>Blood pressure was 110/60 mm Hg.<br>The fasting blood glucose was 107 mg/dl and HbA1c was 6.3%.<br>The chest x-ray showed 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cardiomegaly
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 with a cardiothoracic ratio of 0.67 (figure 1A).<br>ECG, as shown in video 1, revealed a 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    diffused hypokinetic left ventricle
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 with markedly dilated left ventricle dimension (end-diastole: 95 mm) and reduced EF (0.11).<br>The coronary angiogram was normal.<br>A myocardial biopsy revealed that over 50% of cardiomyocytes were replaced by fibrosis (figure 2).<br>An implantable 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cardioverter-defibrillator
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 was implanted.<br>Due to the typical facial appearance and 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    thickening of hands
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
, he was referred to the endocrinology department.<br>The plasma level of GH was 8.2 ng/ml and IGF-1 was 504 ng/ml.<br>MRI demonstrated a 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    macroadenoma in the pituitary
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.<br>Thus, he was diagnosed as 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    acromegaly
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.<br>He was treated with 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    octreotide long-acting-
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
release (LAR) for 8 months.<br>Thereafter, he underwent trans-sphenoidal surgery in January 2009 (figure 3).<br>The plasma levels of GH and IGF-1 were decreased with octreotide LAR, but basal plasma levels of GH were always more than 4 ng/ml and plasma IGF-1 levels were above the appropriate age range (figure 3).<br>After surgery, both plasma levels of GH and IGF-1 further decreased.<br>Basal plasma levels of GH were mostly less than 0.5 ng/ml and IGF-1 levels were within normal ranges (figure 3).<br>With the treatment of LAR, the cardiac function improved partially (cardiothoracic ratio=0.58; EF=0.20 in September 2008).<br>After surgery, the cardiac function improved drastically (cardiothoracic ratio=0.47; EF=0.55 in April 2009; figures 1B and  and2B).2B).<br>Frequency of 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ventricular arrhythmias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 decreased and 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pimobendan
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 was tapered off.<br>A 30-year-old woman with a history of 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    HIV
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    HCV
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 presented to the emergency department with a 4-month history of gradual but progressive 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    swelling of her lower limbs and abdomen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
.<br>She denied any 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    chest pain
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
, 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dyspnoea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    paroxysmal nocturnal dyspnoea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 or 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    orthopnoea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.<br>Vitals were stable.<br>Cardiovascular examination was remarkable for an elevated 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    jugular venous pressure (JVP
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
) of about 12 cm with a pronounced 'y' descent.<br>There was a prominent 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pericardial knock sound
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 heard over the praecordium.<br>There was no pericardial rub or murmur.<br>The lungs were clear to auscultation.<br>The patient was markedly oedematous from the abdomen to the lower limbs.<br>She was admitted for further diagnostic work-up and management.<br>She was diagnosed with 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    HIV
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 around May 2010 and had been on antiretroviral therapy.<br>She had not used illicit drugs for approximately 5-6 years.<br>
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Renal and hepatic diseases
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 were ruled out through blood tests and imaging.<br>Peritoneal fluid was negative for malignancy.<br>Echocardiogram showed a thickened bright pericardium adjacent to the right heart border (figure 1) with parallel separation between epicardial and pericardial echoes (railroad track sign), septal bounce and lack of pericardial slide.<br>
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Annulus paradoxus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 was demonstrated on tissue Doppler (figure 2).<br>Left ventricular ejection fraction was 64%.<br>The right ventricle was normal in size and function.<br>There was moderate tricuspid regurgitation.<br>There was no pericardial effusion, but the pericardial space was remarkable for debris.<br>Constrictive physiology was demonstrated by Doppler study of tricuspid and mitral inflows (figure 3) during inspiration and expiration; diastolic flow reversal was also demonstrated in the hepatic veins during expiration.<br>There was marked dilatation of the inferior vena cava with no change during inspiration or expiration.<br>CT of the chest revealed 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    thickening of the pericardium
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 with no evidence of calcification.<br>There were no 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    lung nodules
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
.<br>Bilateral 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pleural effusions
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 and 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    interstitial thickening
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 were present in the lung bases.<br>Cardiac MRI confirmed the presence of a diffusely thickened pericardium at 5 mm.<br>The inferior vena cava and 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hepatic veins
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 appeared plethoric.<br>There was a rapid early 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    diastolic filling
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 and associated 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    diastolic septal bounce
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 secondary to hindered late diastolic filling (figure 4).<br>The patient showed a good response to 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    diuresis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.<br>She underwent right and left heart catheterisation to confirm constrictive physiology.<br>A 56-year-old African American man who initially presented with 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    diarrhea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
, 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    weight loss
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 and painless 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    jaundice
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
, was subsequently found to have 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    adenocarcinoma
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 of the head of pancreas.<br>An initial workup revealed localized 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cancer
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with no evidence of distant metastases.<br>He then underwent 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pancreaticoduodenectomy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 with complete surgical resection of a 5cm moderately differentiated 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pancreatic adenocarcinoma
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.<br>Although our patient underwent complete surgical resection, a pathological examination revealed a neoplastic invasion of the resected adjacent organs, and one out of the seven resected lymph nodes contained 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cancer
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (T3N1M0).<br>At that point, the oncology department recommended to proceed with adjuvant chemotherapy with 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    gemcitabine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 (1000mg/m2 IV on days 1, 8, 15 on a 28-day cycle for six cycles) to try to reduce the likelihood of recurrence.<br>However, after completing two cycles (a total of six doses) of chemotherapy, he presented to the emergency department with worsening 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    exertional dyspnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
, 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    three-pillow orthopnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
, 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    paroxysmal nocturnal dyspnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 and 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    fatigue
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
.<br>His physical examination revealed an elevated 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    jugular venous pressure (JVP
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
) (10cm above the sternal angle), 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bibasilar rales
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 and 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    +2 pitting edema
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 of both lower extremities.<br>Cardiac auscultation revealed a 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    gallop rhythm
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 with an S3 and a grade 3 holosystolic murmur over precordium.<br>A chest X-ray showed 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cardiomegaly
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 with mild to moderate-sized 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    right-sided pleural effusion
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
.<br>It was thought that his presentation was consistent with 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    fluid overload
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 secondary to 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    congestive heart failure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CHF
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) and he was started on intravenous (IV) 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    furosemide
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 with partial improvement in his symptoms.<br>The next day, a two-dimensional echocardiography (2D Echo) was performed, which showed left ventricular ejection fraction (LVEF) of 15 to 20 percent with global hypokinesia along with moderate mitral regurgitation.<br>Given the findings of 2D Echo and the absence of significant risk factors for coronary 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    artery disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (CAD) and 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ischemic cardiomyopathy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (CMP), it was concluded that our patient's CMP was related to the recent use of gemcitabine.<br>Our patient was then started on carvedilol and an angiotensin
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    -converting
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 enzyme inhibitor in addition to diuretics and he was discharged from the hospital two days later in a euvolemic state.<br>At that point, the cardiology department recommended stopping further chemotherapy with gemcitabine.<br>The oncology department advised further testing to rule out ischemia as a cause of CMP as, in their opinion, chemotherapy with gemcitabine was the only option to reduce the risk of recurrence in this patient.<br>Two weeks later, our patient underwent myocardial perfusion imaging (MPI), which showed a fixed small- to moderate-sized inferior wall defect without any evidence of active 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ischemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.<br>The ejection fraction (EF) on MPI was calculated to be around 17 to 20 percent with severe 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    global hypokinesia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.<br>Our patient was continued on standard 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    heart failure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 therapy with one more admission to the hospital for 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CHF
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 exacerbation about two months later.    <br>He responded well to IV 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    furosemide
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 and adjustment of heart failure therapy.<br>A 2D Echo was repeated a few months later and it showed improvement in 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    systolic function
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 with an LVEF of 40 percent.<br>Due to his poor functional status and underlying CMP, further gemcitabine chemotherapy was stopped.<br>Later, our patient developed a recurrence of his pancreatic 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cancer;
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 he refused further chemotherapy and decided to proceed with palliative care.    <br>Although the exact etiology of our patient's dilated 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cardiomyopathy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 remains unclear, gemcitabine remains the most likely culprit.<br>The temporal relationship of his symptoms to the initiation of gemcitabine chemotherapy; the lack of risk factors for ischemic 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CMP
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and prior history of 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CAD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, finding of global 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypokinesia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 on 2D Echo, absence of 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ischemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 on MPI; and improvement in his systolic function after discontinuation of gemcitabine were all consistent with gemcitabine-induced 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cardiomyopathy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.<br>A 76-year-old woman presented to our hospital with complaints of 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    epigastralgia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 since a day prior to admission.<br>Laboratory data on admission revealed an elevation of 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    aminotransferase
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
, 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    alanine aminotransferase
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
, 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    u-guanosine triphosphate
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
, and 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    alkaline phosphatase
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
.<br>Serum total 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bilirubin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 and tumor markers, carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), SPan-1, and 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neuron-specific enolase
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 (NSE), were all within normal ranges.<br>Abdominal computed tomography (CT) and magnetic resonance cholangiopancreatography (MRCP) showed a mass in an enlarged gallbladder and bulky hepatic lymph nodes surrounding the hepatic hilum (Fig.1a,  b).<br>There were also no apparent lesions in upper and lower gastrointestinal endoscopy.<br>Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) was performed to obtain tissue from the hilar lymph node.<br>Immunohistochemical staining of the specimen identified diffuse positivity for keratin, CD56, and 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    synaptophysin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 in the tumor cells, which is consistent with 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NEC
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.<br>An endoscopic naso-gallbladder drainage (ENGBD) catheter was placed, and the bile cytology revealed class V malignant cells.<br>Therefore, positron emission tomography/computed tomography (PET/CT) examination was performed to evaluate other primary or metastatic lesions.     <br>It revealed that no other accumulated lesions were identified, and the accumulation of 18F fluorodeoxyglucose (FDG) was in the gallbladder (SUVmax 7.8) and lymph nodes (SUVmax 13.4) (Fig.1c, d).<br>On the basis of these findings, the most likely diagnosis was a 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    gallbladder NEC
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 that was confined to the regional hepatic hilar lymph nodes metastasis.<br>Finally, we decided to perform surgical resection prior to chemotherapy because of concerns about complications developing from 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    mechanical obstruction of the hepatic hilum
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 by the enlarged lymph node.<br>She underwent 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cholecystectomy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hepatic hilar
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 lymphadenectomy, 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    extrahepatic biliary duct resection
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
, and 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hepaticojejunostomy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.<br>The bulky lymph nodes were totally resected as &quot;en bloc&quot;.<br>There were no apparent residual lesions surgically.<br>The postoperative course was uneventful and she was discharged on the tenth day after surgery.<br>Macroscopically, the tumor was 58 x 42 mm in size and was located in the fundus, which contained a yellowish gallstone (Fig.2a).<br>A portion of the hepatic hilar lymph nodes (71 x 37 mm) was also excised separately (Fig.2b).<br>Microscopic examination of the gallbladder revealed a moderate to well differentiated 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tubular adenocarcinoma
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 infiltrating from the mucosa to the muscular layer, but not the serosal surface, without any NEC components (Fig.2c,  d).<br>The tumor cells in the gallbladder are slightly positive for synaptophysin and CD56, but negative for 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    chromogranin A
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 (Fig.2e-g).<br>The resection margin from the liver bed was negative for tumor cells.<br>The epithelium around the 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    carcinoma
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 showed 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    intestinal metaplasia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 with the goblet cells (Fig.4a), which area was stained by alcian blue (Fig.4b).    <br>On the other hand, the hepatic hilar lymph nodes were composed of small round tumor cells with hyperchromatic nuclei and scant cytoplasm (Fig.3a).  <br>Some of the tumor cells were large and had vesicular nuclei.<br>The tumor cells were arranged in sheets, cords, or in a trabecular or rosette fashion and were interspersed with focal necrosis.<br>They were immunohistochemically positive for 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CD56
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    synaptophysin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
, and 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    chromogranin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 A (Fig.3b-3d).<br>The mitotic count was 24 per 10 high-power microscopic fields, and the Ki-67 proliferation index was 70-80%, consistent with 
<mark class="entity" style="background: #43B0F1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NEC
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">ORGANIZATION</span>
</mark>
.<br>The surgical dissection margin of the hepatic lymph nodes was microscopically cauterized within the tumor cells.<br>There was no invasion to the extrahepatic biliary duct.<br>As the result of thorough pathological re-evaluation by total segmentation, a negligible area of 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    adenocarcinoma
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 was detected in the lymph nodes (Fig.3e,  f).<br>The adenocarcinoma component and the 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    intestinal metaplastic epithelium in the gallbladder
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 were both positive for CDX2 (Fig.4a), but the neuroendocrine component in hilar lymph nodes was negative for CDX2 (Fig.4b).<br>Postoperatively, the patient received three cycles of 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    carboplatin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 (area under the curve of 5 on day 1 repeated every 21 days) and 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    etoposide
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 (80 mg/m2 on days 1 through 3 repeated every 21 days).<br>During the first course, grade 4 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neutropenia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 occurred and it was managed with 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    prophylactic fluoroquinolones
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
.<br>After 4 months, multiple 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    recurrences in the para-aortic lymph nodes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 were detected, which was pathologically demonstrated via EUS-FNA to be NEC.     <br>The patient underwent second-line chemotherapy with 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    amrubicin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 (24 mg/m2 on days 1 through 3 repeated every 21 days).<br>Grade 4 neutropenia and 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    anemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 developed during the courses, and she needed to receive pegylated granulocyte colony-stimulating factor and 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    red blood cell transfusion
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
.<br>However, she died of progressive disease 8 months after surgery.<br>A 66-year-old Caucasian woman with a history of 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypertension
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 was admitted to our hospital with a recent diagnosis of 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Burkitt lymphoma
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.<br>Her lactate dehydrogenase level was high and the diameter of her mediastinal mass was more than 10cm.<br>Her physical examination was normal, and basal electrocardiography (ECG) showed 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sinus rhythm
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 with a heart rate of 72 beats/minute.<br>Two-dimensional transthoracic echocardiography (TTE; 
<mark class="entity" style="background: #43B0F1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Siemens
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">ORGANIZATION</span>
</mark>
, 
<mark class="entity" style="background: #43B0F1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Acuson Sequoia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">ORGANIZATION</span>
</mark>
, C512) revealed normal biventricular functions with an LV ejection fraction (LVEF) of 60%, mild mitral and tricuspid regurgitation, and moderate pericardial effusion.<br>A risk assessment of the patient put her into a high-risk category and she underwent 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    rituximab
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
-hyperfractionated-
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cyclophosphamide
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
-
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    vincristine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
-
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    doxorubicin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
-
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dexamethasone
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 (R-Hyper-CVAD) chemotherapy protocol.<br>Her laboratory values are summarized in Table 1.<br>She received high-dose 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cyclophosphamide
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 300mg/m2 twice daily for 3 days, 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    doxorubicin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 25mg/m2/day for 2 days, 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    rituximab
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 375mg/m2/day for 1 day, 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dexamethasone
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 40mg/day for 4 days, and 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    vincristine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 2mg/day for 2 days.<br>The total treatment dose of cyclophosphamide and doxorubicin received was 1800mg/m2 and 50mg/m2, respectively.<br>She was given 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    allopurinol
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 300mg/day perorally, 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    sodium bicarbonate
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 (8.4%, 10 flacon/day) infusion for 24 hours before chemotherapy, and 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    mesna
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 600mg/m2/day for 2 days as prophylaxis against 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tumor lysis syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hemorrhagic cystitis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
, respectively.<br>She also received 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    granisetron
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 2mg/day and 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    lansoprazole
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 30mg/day as antiemetogenic and gastric prophylaxis, respectively.<br>The patient developed 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dyspnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 on the seventh day of therapy.<br>A physical examination revealed 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    blood pressure of 100/60mmHg and
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 a 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    heart rate of 110 beats/minute
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
.<br>On chest auscultation, no inspiratory sounds were heard at lower zones and 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    inspiratory crackles
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 were heard at middle zones.<br>Neither cardiac murmurs nor S3 were heard.<br>An ECG showed low voltage in the limb and precordial leads.<br>TTE showed diffusely increased 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myocardial echogenicity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
, mild 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pericardial effusion
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
, and generally impaired 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    biventricular systolic functions
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 with an LVEF 31% and 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    right ventricular mid-apical akinesis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
.<br>Manifest 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pleural effusion
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 was also detected.<br>Drug-induced 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cardiotoxicity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 (
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myocarditis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
) was suspected.<br>
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Furosemide
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 and 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ramipril
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 were started.<br>The 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    beta-
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
blocker therapy the patient was already taking for 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypertension
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 was continued.<br>After 12 days, TTE showed an LVEF of 37% and normal right ventricular functions.<br>Her 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dyspnea
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 decreased and she was discharged on day 20.<br>After 1 month, TTE showed normal biventricular functions with an LVEF of 60%.<br>After the first course of the 
<mark class="entity" style="background: #EC8FD0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    R-Hyper-CVAD chemotherapy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">VACCINE-RELATED</span>
</mark>
 protocol, she underwent a high-dose 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    methotrexate
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 and 
<mark class="entity" style="background: #dcedc1; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cytarabine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DRUG</span>
</mark>
 cycle.<br>She had severe 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neutropenia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
 and 
<mark class="entity" style="background: #a8e6cf; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pneumonia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DISEASE</span>
</mark>
.<br>She had no 
<mark class="entity" style="background: #ffaaa5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cardiac failure symptoms
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">SYMPTOM</span>
</mark>
 during this chemotherapy course, but she declined another course of chemotherapy.<br>She is still in remission despite the abbreviated course of chemotherapy.</div>